Venus Remedies gets marketing approval for cancer drugs from Uzbekistan, Palestine
Venus Remedies is expected to launch these drugs in the two countries in the next financial year
Venus Remedies has received marketing authorisations for its generic cancer drugs from Uzbekistan and Palestine. The marketing approval for Carboplatin in Uzbekistan and Docetaxel and Irinotecan in Palestine will help the company to expand its footprint in Central Asia and Middle East.
Venus Remedies is expected to launch these drugs in the two countries in the next financial year.
Dr Manu Chaudhary, Joint MD, Venus Remedies said that the marketing authorisations would help Venus Remedies further strengthen its oncology portfolio and improve its presence in the oncology space.
“The two markets offer a great opportunity to us and we are aiming at capturing a sizeable share in these markets through the three cancer drugs in the very first year of their launch. We will continue to invest in our generic drug portfolio and expand to new geographies,” said Chaudhary.
The company is contributing substantially in the oncology segment across the globe through its wide array of key products, which include Docetaxel, Paclitaxel, Gemcitabine, Oxaliplatin, Bortezomib and Pemetrexed.